Clinical Trial Search

Primary: Absolute Value of LVEF Percentage Differences From CMR by Blinded Reader — 6.10; 6.38; 4.93; 6.18 Percent Ejection Fraction — p=0.868

Primary: Change in Cardioendocrine Risk by Surrogate Blood Measures of the Homeostasis Model Assessment - Insulin Resistance (HOMA 2-IR) — 1.67; 1.60 IR Score

Primary: Mean Scores of a Questionnaire Evaluating Patient Confidence in Navigating Vascular Access Care Pre- to Post-program Implementation — 8.0; 8.7 score on a scale — p=0.20

Primary: Baseline Patient Characteristics: Age — 71.6; 72.1; 70.9 years — p=0.2810

Primary: Change in Body Fat as Measured by Bod Pod — 15.5; 16.2; 14.8; 15.3 Percent Body Fat

Primary: Percentage of Microbiologic Modified Intent to Treat Resistant (Micro-MITTR) Participants With Overall Success — 62.6; 36.0 percentage of participants

Primary: Pain Scores 48 Hours After Surgery — 118.4; 98.2 Scores*Hour — p=0.41

Primary: Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS) — 32.67; 27.4; 33.67; 27.33 score on a scale

Primary: Percentage of Participants With Clinical Cure at Test of Cure (TOC) in Participants With HAP/VAP/HCAP or BSI/Sepsis — 50.0; 52.6; 43.5; 42.9 percentage of participants

Primary: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -12; -12; -12 score on a scale

Primary: Pharmacokinetic (PK) Parameter: AUClast of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate) — 160.6…

Primary: Overall Survival (OS) — 21.4; 14.3 months — p=0.0005

Primary: Incidence of Grade 3+ Gastrointestinal Toxicity — 0 participants

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) - Q3W Regimen — 0; 0; 0; 0 Participants

Primary: Proportion of Patients With a Positive SARS-CoV-2 PCR — 12; 12; 11; 12 Participants